---
title: Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires
  the ABL SH3 domain for efficacy
date: '2024-06-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38848536/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240608181749&v=2.18.0.post9+e462414
source: Blood
description: High-risk Ph-like ALL includes genomic rearrangement of the ABL1 and
  ABL2 genes (collectively ABL-rearranged, ABLr), and novel treatments are required.
  For the first time, we demonstrate asciminib efficacy in ABLr ALL, but only when
  the ABL SH3 domain is ...
disable_comments: true
---
High-risk Ph-like ALL includes genomic rearrangement of the ABL1 and ABL2 genes (collectively ABL-rearranged, ABLr), and novel treatments are required. For the first time, we demonstrate asciminib efficacy in ABLr ALL, but only when the ABL SH3 domain is ...